Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Penile Cancer Clinical Trial

— MEGACEP  

Official title:

Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02817958
• Other study ID #: UC-0160/1406
• Secondary ID: AFU-GETUG 252014
• Status: Recruiting
• Phase: Phase 2
• Start date: October 17, 2016
• Est. completion date: September 2028

Study information

• Verified date: November 2023
• Source: UNICANCER
• Contact: Sandra PELISSIER
• Phone: +33(0)144235568
• Email: s-pelissier[@]unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Squamous cell carcinoma of the penis is a rare tumor in Europe, whose prognosis and survival are influenced by metastatic lymph node involvement. Its frequency in France is estimated at less than 1% of human cancers. This spread follows a sequential process via the superficial and deep inguinal lymph nodes and then to the pelvic lymph nodes before metastatic dissemination.

The management of inguinal areas is the cornerstone of penile cancer. It is curative in about 80% of patients with 1 or 2 inguinal metastases. 5-years overall survival was on average 85% for pN0 patients and 40% for pN+ patients. For pN+ patients, 5-year overall survival was 70 to 80% for pN1 (only 1 lymph node invasion), 30 to 40% for pN2, and 0 to 10% for pN3.

The risk of local recurrence is 5-10% for pN0 and 20-30% for pN+ after local treatment by lymphadenectomy alone without chemotherapy. The average time to recurrence was 10 months. Disease-free survival at 5 years is 75-85% for pN0 and 30-45% for pN+. Its indication depends on clinical examination (presence or absence of lymph nodes palpated) and the risk of nodal disease (≥pT1bG2).

Currently, a fine needle biopsy is the best clinical diagnosis method because it is a simple, low risk, and possible in consultation. When the result is positive, it allows an early dissection. Single or double fine needle biopsy will be used in cN+ patients. For patients at risk of lymp nodes involvement (cN0 and ≥pT1B or G2), the sentinel node diagnosis may be followed by modified or bilateral lymphadenectomy.

Although lymphadenectomy alone has a curator action, it sometimes remains insufficient in patients with metastatic lymph node involvement. Therefore it seems important to develop a multimodal approach in the management of these patients in order to increase the response rate to treatment and survival.

From a Phase II trial conducted on 30 patients, the combination TIP (paclitaxel, ifosfamide, and cisplatin) appears to have an efficacy / toxicity acceptable.

The TIP protocol has therefore been chosen for this trial as adjuvant or neo-adjuvant treatment in patients with high risk of lymph nodes involvement (cN0 and ≥pT1B or G2), and with inguinal mobile palpated lymph nodes (cN+) respectively, after lymph nodes involvement proven (pN+).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 37
• Est. completion date: September 2028
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. penile tumor histologically proven whatever the initial treatment of penile tumor:

amputation or conservative surgery or brachytherapy,

2. Mobile palpated lymph nodes (stage cN1 and cN2) whatever the T stage, Or If no palpated lymph nodes (cN0), patients with nodes involvement risk =pT1b and / or Grade 2,

3. Metastatic lymph node involvement,

4. Patients M0 or Mx,

5. Age =18 ans,

6. Eastern Cooperative Oncology Group (ECOG) 0-1,

7. Leucocytes =1.5 g/L,

8. Hemoglobin =9 g/dL,

9. Platelets =100 000/mm³,

10. Normal calcemia and kaliemia,

11. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =1.5 upper limit of normal (ULN) ; total bilirubin =1.5 ULN (3 ULN in case of Gilbert disease); alkaline phosphatase (ALP) <2 ULN,

12. Creatinine clearance =60 mL/min (MDRD method),

13. Left ventricular ejection fraction (LVEF) >50%,

14. Patients having received, read the information note and signed consent,

15. Reproductive age patients agreeing to use two methods of birth control (one for the patient and one for the partner) for the duration of the study and for 6 months after the last dose of treatment,

16. Patients able to comply with the protocol requirements (scheduled visits, treatment plan, clinical, paraclinical, biological and other procedures of the Protocol),

17. Patients undergoing a social security scheme.

Exclusion Criteria:

1. Fixed inguinal lymph nodes (cN3),

2. Iliac lymph nodes (cN3),

3. Patients pN3,

4. prior chemotherapy for squamous cell carcinoma of the penis,

5. Against-indication for chemotherapy or known hypersensitivity to cisplatin, ifosfamide or paclitaxel,

6. Patients treated with phenytoin,

7. Patients with hearing loss >Grade 1 (CTCAE V4.03),

8. Patients with cardiopulmonary disease-indicating against overhydration,

9. History of cancer within 5 years prior to inclusion in the trial other than cutaneous basal cell,

10. Patient received a live attenuated vaccine within 30 days prior to inclusion,

11. Patients already included in another clinical trial or receiving an experimental treatment within 30 days prior to inclusion in the trial,

12. Patients deprived of their liberty or under court protection including guardianship,

13. Severe systemic disease or uncontrolled or any other chronic or acute illness that is incompatible with the patient's participation in the trial according to investigator,

14. immunocompromised patients including with known seropositivity (HIV),

15. Patients with mental impairment which prevents the understanding of the protocol or having a psychological state, family, sociological or geographical conditions that would not allow compliance with the protocol and the planned follow-up or any condition which, according to the investigator, would prevent participation patient tested. These conditions should be assessed before inclusion of patients.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Penile Cancer
• Penile Neoplasms
• Squamous Carcinoma

Intervention

Drug:
• Chemotherapy TIP
Paclitaxel, ifosfamide, and cisplatin

Locations

Country	Name	City	State
France	ICO-Paul Papin	Angers
France	Chr Besancon	Besançon
France	Hôpital SAINT ANDRE	Bordeaux
France	Centre FRANCOIS BACLESSE	Caen
France	Chru Gabriel Montpied	Clermont Ferrand
France	Ch de Limoges	Limoges
France	Centre Leon Berard	Lyon
France	Chu Lyon Sud	Lyon
France	Institut Paoli-Calmettes	Marseille
France	Institut de Cancerologie de Lorraine	Nancy
France	Clinique Urologique- Chu Hotel Dieu	Nantes
France	Institut de Cancerologie Du Gard - Centre Oncogard	Nîmes
France	Hopital Saint Louis	Paris
France	Chu de Rouen	Rouen
France	ICO-René Gauducheau	saint Herblain
France	Hopitaux Universitaires de Strasbourg	Strasbourg
France	Institut Claudius Regaud	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
UNICANCER	National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival without locoregional lymph node recurrence	checked by inguinal ultrasound	24 months
Secondary	Complete response rate for patients in neoadjuvant chemotherapy	lack of residual tumor post surgical histopathology	6 months
Secondary	Survival without locoregional lymph node recurrence	time between inclusion and locoregional recurrence or last evaluation	3 years
Secondary	Survival without metastasis	time between inclusion and the date of occurrence of metastases	3 years
Secondary	Specific survival	time between inclusion and date of death from penile cancer or treatment-related complication	3 years
Secondary	Overall survival	time between inclusion and the death regardless of cause	3 years
Secondary	Acute and late toxicity during the study	The National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE v4.03) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3; = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.	Throughout study completion, up to 3 years
Secondary	Quality of life questionnaire - Core 30 (QLQ-C30)	Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.	baseline, during treatment (C3J42), 6 month, 1 year